• Atossa Therapeutics highlighted preclinical study results for (Z)-endoxifen in Duchenne muscular dystrophy that were already presented March 11, 2026 at MDA Clinical & Scientific Conference.
• Data indicated (Z)-endoxifen improved muscle function and body composition in dystrophic mouse models, supporting a move toward clinical testing.
• FDA granted Orphan Drug designation for (Z)-endoxifen in Duchenne muscular dystrophy in January 2026, strengthening regulatory positioning for a potential rare-disease development path.
• FDA also granted Rare Pediatric Disease designation for (Z)-endoxifen in McCune-Albright Syndrome in early May 2026, creating potential eligibility for a Priority Review Voucher upon approval of a qualifying marketing application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-213439), on May 08, 2026, and is solely responsible for the information contained therein.